Frontier gets $80M, Galapagos’ backing to make a better KRAS drug

Biotechnology startup Frontier Medicines has pulled in $80 million in new funding to support a targeted cancer drug the company thinks might address some of the limitations of medicines from Amgen and Mirati Therapeutics.